Healthdirect Free Australian health advice you can count on.
Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately
healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.
NSW Health Alert: Any patients who have received dental treatment from Mr Safuan (Steven) Hasic at 70 Victoria Ave, Mortdale NSW 2223 may
be at risk of blood-borne viruses and should see their GP for precautionary testing. More information is available from
NSW Health
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Intragam P is indicated in replacement Immunoglobulin G (IgG) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. INDICATIONS AS AT 21 JULY 2000: Replacement IgG therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. Immunomodulatory therapy in: idiopathic thrombocytopenic purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; Kawasaki disease. INDICATIONS AS AT 25 FEBRUARY 2003: For replacement immunoglobulin G (IgG) therapy in: Primary immunodeficiency; Myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; Congenital acquired immune deficiency syndrome with recurrent infections. For immunomodulatory therapy in: Idiopathic thrombocytopenic purpura (ITP) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; Allogeneic bone marrow transplantation; Kawasaki disease, and; Guillain-Barre Syndrome (GBS).
Intragam P is indicated in replacement Immunoglobulin G (IgG) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. INDICATIONS AS AT 21 JULY 2000: Replacement IgG therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. Immunomodulatory therapy in: idiopathic thrombocytopenic purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; Kawasaki disease. INDICATIONS AS AT 25 FEBRUARY 2003: For replacement immunoglobulin G (IgG) therapy in: Primary immunodeficiency; Myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; Congenital acquired immune deficiency syndrome with recurrent infections. For immunomodulatory therapy in: Idiopathic thrombocytopenic purpura (ITP) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; Allogeneic bone marrow transplantation; Kawasaki disease, and; Guillain-Barre Syndrome (GBS).
Intragam P is indicated in replacement Immunoglobulin G (IgG) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. INDICATIONS AS AT 21 JULY 2000: Replacement IgG therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. Immunomodulatory therapy in: idiopathic thrombocytopenic purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; Kawasaki disease. INDICATIONS AS AT 25 FEBRUARY 2003: For replacement immunoglobulin G (IgG) therapy in: Primary immunodeficiency; Myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; Congenital acquired immune deficiency syndrome with recurrent infections. For immunomodulatory therapy in: Idiopathic thrombocytopenic purpura (ITP) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; Allogeneic bone marrow transplantation; Kawasaki disease, and; Guillain-Barre Syndrome (GBS).
Intragam P is indicated in replacement Immunoglobulin G (IgG) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. INDICATIONS AS AT 21 JULY 2000: Replacement IgG therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. Immunomodulatory therapy in: idiopathic thrombocytopenic purpura (ITP), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; Kawasaki disease. INDICATIONS AS AT 25 FEBRUARY 2003: For replacement immunoglobulin G (IgG) therapy in: Primary immunodeficiency; Myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; Congenital acquired immune deficiency syndrome with recurrent infections. For immunomodulatory therapy in: Idiopathic thrombocytopenic purpura (ITP) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; Allogeneic bone marrow transplantation; Kawasaki disease, and; Guillain-Barre Syndrome (GBS).
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
